98%
921
2 minutes
20
Cholesterol metabolism provides cell and organelle membrane components, and its precursors and derivatives exert a variety of biological functions. Dysregulated cholesterol metabolism has emerged as a hallmark of tumors. In the tumor microenvironment, cell-intrinsic and cell-extrinsic cues reprogram cholesterol metabolism to drive tumorigenesis and tumor development. Clinical studies and mechanistic investigations into cholesterol metabolism pathways have uncovered novel metabolic vulnerabilities that hold promise for cholesterol metabolism-targeted therapies for cancer. Moreover, recent studies highlight that manipulating cholesterol metabolism could reshape the immunological landscape and re-boost anti-tumor immunity. Thus, it is critical to deeply discuss the role of cholesterol metabolism in tumors and immune microenvironment to extend this knowledge into current immunotherapies. In this review, we summarize current insights into reprogrammed cholesterol metabolism in tumors and explore the complex interplay between cholesterol metabolism and anti-tumor immunity in diverse immune components within the tumor microenvironment. These findings may provide novel clinical strategies for targeting cholesterol metabolism in the context of cancers.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.bbcan.2025.189422 | DOI Listing |
J Orthop Sci
September 2025
Hirosaki University Graduate School of Medicine, Department of Orthopedic Surgery, Hirosaki, Aomori, Japan.
Background: The concept of early-phase diffuse idiopathic skeletal hyperostosis (EDISH) was recently introduced and its prevalence at the thoracic spine level was revealed. Some cases of EDISH progress to diffuse idiopathic skeletal hyperostosis (DISH) in association with being overweight. The prevalence and distribution of EDISH in the whole spine and related factors are unclear.
View Article and Find Full Text PDFJ Steroid Biochem Mol Biol
September 2025
Biochemistry and Phytochemistry Research Division, Jubilee Centre for Medical Research, Thrissur, Kerala, 680005, India. Electronic address:
7-Ketocholesterol (7-KC) is a biologically active oxysterol formed through the oxidation of cholesterol, predominantly under conditions of oxidative stress. It is generated both enzymatically in specific tissues such as the brain and liver, and non-enzymatically via reactive oxygen species (ROS), especially in aging tissues and heat-processed animal-derived foods. 7-KC exerts multifaceted effects on human health, extending beyond lipid metabolism to disrupt glucose and amino acid utilization, impair mitochondrial function, and provoke endoplasmic reticulum (ER) stress.
View Article and Find Full Text PDFJ Nutr
September 2025
Institute of Food and One Health, Leibniz University Hannover, 30167 Hannover, Germany.
Background: Dietary fiber supports metabolic health via microbial fermentation, producing short-chain fatty acids (SCFAs). However, metabolic responses to fiber vary between individuals, potentially due to differences in gut microbiota composition. The Prevotella-to-Bacteroides (P/B) ratio has emerged as a potential biomarker for fiber responsiveness.
View Article and Find Full Text PDFEur J Pharmacol
September 2025
Department of Pharmacy, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, P. R. China; Henan Key Laboratory of Precision Clinical Pharmacy, Zhengzhou, P. R. China. Electronic address:
Drug-induced liver injury is a major cause of acute liver failure. Crizotinib is a first-line treatment for patients with cellular-mesenchymal epithelial transition factor (c-MET), anaplastic lymphoma kinase (ALK), and ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer. Although some patients treated with crizotinib experience hepatic adverse effects, the underlying mechanisms remain unclear.
View Article and Find Full Text PDFInt Immunopharmacol
September 2025
Transplantation Center, Third Xiangya Hospital, Central South University, Changsha 410013, Hunan, China; Key Laboratory of Translational Research in Transplantation Medicine of National Health Commission, Third Xiangya Hospital, Central South University, Changsha 410013, Hunan, China; Clinical Resea
Kidney transplantation (KT) is an effective treatment for end-stage renal disease, with over 90 % of recipients requiring lifelong tacrolimus (Tac). However, The Tac pharmacokinetics exhibit high intra-patient variability (IPV), posing significant challenges. This study included 102 KT recipients at our center from October 2022 to December 2023.
View Article and Find Full Text PDF